secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001193125-23-160355
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic initiates Phase 3 PKU study SYNB1934, cuts workforce 21%
-----------------------------------------------------------------

- Initiated Synpheny-3 global pivotal Phase 3 trial of SYNB1934 for phenylketonuria (PKU), targeting ~150 patients.
- Primary endpoint: change in plasma phenylalanine after 4-week placebo-controlled randomized withdrawal.
- Workforce reduced by ~21%; expects $0.9M in severance costs in Q2/Q3 2023.
- Cash runway extended into H2 2024 by prioritizing SYNB1934 and SYNB1353 programs.
- Study design includes virtual/hybrid options; ages 18+ with potential expansion to 12+.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312523160355/0001193125-23-160355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312523160355/d232864d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-160355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer